Page 29 - Read Online

RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23.
Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus 86. Kulke MH, Niedzwiecki D, Foster NR, Fruth B, Kunz PL,
octreotide long-acting repeatable for the treatment of advanced Kennecke HF, Wolin EM, Venook AP. Randomized phase II Study
neuroendocrine tumours associated with carcinoid syndrome of Everolimus versus Everolimus plus Bevacizumab in patients
(RADIANT-2): a randomised, placebo-controlled, phase 3 study. with locally advanced or metastatric panxcreatic neuroencocrine
Lancet 2011;378:2005-12. tumors CALG80701 (Alliance). Proceedings of 2015 ASCO Annual
81. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, meeting. J Clin Oncol 2015;33:15S, abs 4005.
Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre 87. Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind
N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, JF, Pawlik TM. Emerging approaches in the management of patients
Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 with neuroendocrine liver metastasis: role of liver-directed and
in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) systemic therapies. J Am Coll Surg 2013;216:123-34.
Study Group. Everolimus for the treatment of advanced, non- 88. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark
functional neuroendocrine tumours of the lung or gastrointestinal H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K,
tract (RADIANT-4): a randomised, placebo-controlled, phase 3 Eriksson B, Skogseid B. Temozolomide as monotherapy is effective
study. Lancet 2016;387:968-77. in treatment of advanced malignant neuroendocrine tumors. Clin
82. Raymond E, Dahan L Raoul JL, Bang YJ, Borbath I, Lombard- Cancer Res 2007; 13:2986-91.
Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch 89. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R,
D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment
Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for of patients with locally advanced and metastatic pancreatic
the treatment of pancreatic neuroendocrine tumors. N Engl J Med endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
2011;364:501-13. 90. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT,
83. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Helm J, Kvols L. First-line chemotherapy with capecitabine and
Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia- temozolomide in patients with metastatic pancreatic endocrine
del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim carcinomas. Cancer 2011;117:268-75.
ST, Chen I, Huang X, Figlin RA. Overall survival and updated 91. Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi
results for sunitinib compared with interferon alfa in patients with L, Bodei L, Torta M, D’Avolio A, Priola AM, Birocco N, Amoroso
metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90. V, Biasco G, Papotti M, Dogliotti L. Bevacizumab plus octreotide
84. Oxboel J, Binderup T, Knigge U, Kjaer A. Quantitative gene- and metronomic capecitabine in patients with metastatic well-to-
expression of the tumor angiogenesis markers vascular endothelial moderately differentiated neuroendocrine tumors: the xelbevoct
growth factor, integrin alphaV and integrin beta3 in human study. BMC Cancer 2014;14:184.
neuroendocrine tumors. Oncol Rep 2009;21:769-75. 92. Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY,
85. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung Chayvialle JA, Lombard-Bohas C. Evaluation of the combination
SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced
endothelial growth factor in advanced carcinoid tumor: a random well-differentiated neuroendocrine tumors. Clin Colorectal Cancer
assignment phase II study of depot octreotide with bevacizumab 2010;9:248-54.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦ 303